Influenza A And B Virus Infections Therapeutics
1. Relenza patent expiration
Treatment: Prophylaxis of influenza
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5360817 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-N-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2013
(12 years ago) | |
| US6294572 | GLAXOSMITHKLINE | Crystalline N-acetyl neuraminic acid derivatives and process for their preparation |
Dec, 2014
(11 years ago) | |
| US5648379 | GLAXOSMITHKLINE | Derivatives and analogues of 2-deoxy-2,3-didehydro-n-acetyl neuraminic acid and their use as antiviral agents |
Jul, 2014
(11 years ago) | |
Drugs and Companies using ZANAMIVIR ingredient
Market Authorisation Date: 26 July, 1999
Dosage: POWDER
More Information on Dosage
RELENZA family patents
